- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02887287
Efficacy of Exclusive Enteral Nutrition in Adult Active Crohn's Disease
September 1, 2016 updated by: Yanhong Deng, Sun Yat-sen University
The study aimed to prove EEN is effective for inducing early clinical remission, mucosal healing, promoting fistula closure and reducing the size of abscess to adult CD patients.
They plan to include about 50 patients and observe the effect of EEN.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
48
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- The six affiliated hospital of Sun Yat-sen University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
The detailed inclusion criteria included: 1. >18 years old 2. Patients with CD was diagnosed clinically according to previously established international criteria [9] 3. The diagnosis of stricture, fistula and abdominal abscess was confirmed by ultrasound, CT enterography (CTE), and endoscopy.
The bowel stricture should mainly cause by inflammation but not fibrosis.
Intolerance or failure to steroids or IFX was judged by medical history 4. The disease was in an active period.
Description
Inclusion Criteria:
- >18 years old
- Patients with CD was diagnosed clinically according to previously established international criteria [9]
- The diagnosis of stricture, fistula and abdominal abscess was confirmed by ultrasound, CT enterography (CTE), and endoscopy. The bowel stricture should mainly cause by inflammation but not fibrosis.
Exclusion Criteria:
- Patients do not macth the inclusion criteria and those who refuse to taking part in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Clinical remission after 12 weeks EEN
Time Frame: July 2013 to October 2015
|
July 2013 to October 2015
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2013
Primary Completion (ACTUAL)
October 1, 2015
Study Registration Dates
First Submitted
August 29, 2016
First Submitted That Met QC Criteria
September 1, 2016
First Posted (ESTIMATE)
September 2, 2016
Study Record Updates
Last Update Posted (ESTIMATE)
September 2, 2016
Last Update Submitted That Met QC Criteria
September 1, 2016
Last Verified
August 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- E2016008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.